Answers are grounded in this paper and cite their sources.
Background: Fecal and immunological biomarkers can be used to diagnose and manage patients with Crohn's disease (CD). Antitumor necrosis factor (TNF) should be evaluated in addition to biomarkers to determine the response to therapy.
No takes yet. Share an insight, caveat, or question.
Velikova et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: